SID.ir New Version

Paper Information

Journal:   IRANIAN RED CRESCENT MEDICAL JOURNAL (IRCMJ)   OCTOBER 2013 , Volume 15 , Number 10; Page(s) 0 To 0.
 
Paper: 

Botulinum Toxin Type A Therapy In Migraine: Preclinical And Clinical Trials

 
 
Author(s):  Shao Yu Feng, Zhang Yi, Zhao Pengjun, Yan Wen Jun, Kong Xiang Pan, Fan Lin Lan, Hou Yi Ping*
 
* MEDICAL EXPERIMENTAL CENTER, SCHOOL OF BASIC MEDICAL SCIENCES, LANZHOU UNIVERSITY, LANZHOU, CHINA
 
Abstract: 
Introduction: Botulinum toxin type A (BTX-A) has been reported to be effective for the therapy for migraine. The purpose of this study was to investigate the effect of BTX-A on the immunoreactive levels of calcitonin gene-related peptide (CGRP) and substance P (SP) in the jugular plasma and medulla oblongata of migraine in rats induced by nitroglycerin (NTG), and then to evaluate and compare the effectiveness of fixed (muscle)-sites and acupoint-sites injection of BTX-A for migraine therapy of patients in a randomly controlled trial extending over four months.Materials and Methods: Rats with NTG-induced migraine were subcutaneously injected with vehicle or BTX-A (5 U/kg or 10 U/kg bodyweight). CGRP-and SP-like immunoreactivity (CGRP-LI and SP-LI) were determined by radioimmunoassay. In clinical trials, sixty patients respectively received BTX-A (2.5 U each site, 25 U per patient) at fixed-sites (group F, n=30) including occipitofrontalis, corrugator supercili, temporalis and trapezius or at acupoint-sites (group A, n=30) including EX-HN3, EX-HN5, GV20, GB8, GB20 and BL10.Results: Local BTX-A injection suppressed NTG-induced CGRP-LI and SP-LI levels in jugular plasma and oblongata. BTX-A injection for both groups with migraine significantly reduced the attack frequency, intensity, duration and associated symptoms. The efficacy of BTX-A for migraine in group A (93% improvement) was more significant than that in group F (83% improvement) (P<0.01).Conclusions: The evidence that BTX-A decreases NTG-induced CGRP-LI and SP-LI levels in trigeminovascular system suggests that BTX-A attenuates migraine by suppression of neuropeptide release. BTX-A injections for migraine at acupoint-sites and fixed-sites are effective. Acupoint-sites BTX-A administration shows more efficacy for migraine than fixed-sites application.
 
Keyword(s): BOTULINUM TOXIN TYPE A, NITROGLYCERIN, RANDOMIZED CONTROLLED TRIAL
 
 
International related papers: 
 
Most related Highly related Moderately related Least related
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

SHAO, Y., & ZHANG, Y., & ZHAO, P., & YAN, W., & KONG, X., & FAN, L., & HOU, Y. (2013). BOTULINUM TOXIN TYPE A THERAPY IN MIGRAINE: PRECLINICAL AND CLINICAL TRIALS. IRANIAN RED CRESCENT MEDICAL JOURNAL (IRCMJ), 15(10), 0-0. https://www.sid.ir/en/journal/ViewPaper.aspx?id=411113



Vancouver: Copy

SHAO YU FENG, ZHANG YI, ZHAO PENGJUN, YAN WEN JUN, KONG XIANG PAN, FAN LIN LAN, HOU YI PING. BOTULINUM TOXIN TYPE A THERAPY IN MIGRAINE: PRECLINICAL AND CLINICAL TRIALS. IRANIAN RED CRESCENT MEDICAL JOURNAL (IRCMJ). 2013 [cited 2022August14];15(10):0-0. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=411113



IEEE: Copy

SHAO, Y., ZHANG, Y., ZHAO, P., YAN, W., KONG, X., FAN, L., HOU, Y., 2013. BOTULINUM TOXIN TYPE A THERAPY IN MIGRAINE: PRECLINICAL AND CLINICAL TRIALS. IRANIAN RED CRESCENT MEDICAL JOURNAL (IRCMJ), [online] 15(10), pp.0-0. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=411113.



 
  pdf-File
Yearly Visit 38
 
 
Latest on Blog
Enter SID Blog